1. Home
  2. BANC vs IMNM Comparison

BANC vs IMNM Comparison

Compare BANC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banc of California Inc.

BANC

Banc of California Inc.

HOLD

Current Price

$17.64

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$21.35

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANC
IMNM
Founded
1941
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.5B
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
BANC
IMNM
Price
$17.64
$21.35
Analyst Decision
Buy
Strong Buy
Analyst Count
12
15
Target Price
$22.00
★ $36.00
AVG Volume (30 Days)
★ 2.2M
1.1M
Earning Date
10-27-2026
11-05-2026
Dividend Yield
★ 2.71%
N/A
EPS Growth
★ 125.00
51.40
EPS
N/A
★ N/A
Revenue
★ $1,818,792,000.00
$6,941,000.00
Revenue This Year
$4.16
N/A
Revenue Next Year
$11.72
$18,747.97
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$15.33
$13.41
52 Week High
$21.93
$30.06

Technical Indicators

Market Signals
Indicator
BANC
IMNM
Relative Strength Index (RSI) 40.52 34.01
Support Level $16.35 $19.39
Resistance Level $17.74 $23.25
Average True Range (ATR) 0.43 1.10
MACD -0.03 -0.33
Stochastic Oscillator 43.72 11.57

Price Performance

Historical Comparison
BANC
IMNM

About BANC Banc of California Inc.

Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: